Does aprotinin administration in the pericardial cavity prevent platelet activation?
We conclude that administration of aprotinin into the pericardial cavity during cardiopulmonary bypass and at concentrations similar to the systemic application does not reduce platelet activation in that compartment or the systemic circulation.
PTX-3, a novel inflammatory marker, was found to be associated with the severity of MS.